Preparation of orpiment nanoparticles and their cytotoxic effect on cultured leukemia K562 cells

Journal of Nanoscience and Nanotechnology

Volumn 7, Issue 2, 2007, Pages 490-496

  Lin, Mei ^a   Wang, Ziyu ^b   Zhang, Dongsheng ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

K562 cell; Nanoparticles; Nanotechnology; Orpiment; Tumor

Indexed keywords

ANTITUMOR EFFECTS; APOPTOSIS; CONCENTRATION (COMPOSITION); CYTOMETRY; CYTOTOXIC EFFECTS; ENERGY DISPERSIVE SPECTROMETRY (EDS); K562 CELLS; TIME-DEPENDENT; TRANSMISSION ELECTRON MICROSCOPE (TEM); TWO TYPES;

ANTINEOPLASTIC AGENT; ARSENIC TRISULFIDE; NANOPARTICLE; ORGANOARSENIC DERIVATIVE; SULFIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN K 562; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ERYTHROLEUKEMIA; FLOW CYTOMETRY; HUMAN; IC 50; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; PARTICLE SIZE; PATHOLOGY; SPECTROPHOTOMETRY; TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; SPECTROPHOTOMETRY; SULFIDES; TIME FACTORS;

EID: 34249851027     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2007.145     Document Type: Article

References (23)

1. Y. Deng, H. Xu, K. Huang, X. Yang, C. Xie, and J. Wu, Pharmacol. Res. 44, 513 (2001).
2. H. Y. Hao, Z. P. Teng, and D. P. Lu, Zhongguo Shi Yan Xue Ye Xue Za Zhi 10, 108 (2002).
3. Y. H. Du and P. C. Ho, Cancer Chemother Pharmacol. 47, 481 (2001).
4. G. A. Soto-Pena, A. L. Luna, L. Acosta-Saavedra, P. Conde-Moo, L. Lopez-Carrillo, M. E. Cebrian, M. Bastida, E. S. Calderon-Aranda, and L.Vega, FASEB J. 6 (2006).
5. S. Bashir, Y. Sharma, M. Irshad, S. D. Gupta, and T. D. Dogra, Basic Clin Pharmacol. Toxicol. 98, 38 (2006).
6. Y. Gonzalez-Rangel, D. P. Portales-Perez, O. Galicia-Cruz, and C. Escudero-Lourdes, Proc. West Pharmacol. Soc. 48, 89 (2005).
7. T. Sakurai, T. Ohta, N. Tomita, C. Kojima, Y. Hariya, A. Mizukami, and K. Fujiwara, Int Immunopharmacol. 6, 304 (2006).
8. M. Rahman, M. Vahter, M. A. Wahed, N. Sohel, M. Yunus, P. K. Streatfield, S. E. Arifeen, A. Bhuiya, K. Zaman, A. M. Chowdhury, E. C. Ekstrom, and L. A. Persson, J. Epidemiol Community Health 60, 242 (2006).
9. A. B. Josyula, G. S. Poplin, M. Kurzius-Spencer, H. E. McClellen, M. J. Kopplin, S. Sturup, R. Clark-Lantz, and J. L. Burgess, Environ Res. 15 (2006).
10. K. R. Manygoats, M. Yazzie, and D. M. Stearns, J. Biol. Inorg. Chem. 7, 791 (2002).
11. A. Fidzianska, Folia Neuropathol 40, 27 (2002).
12. S. Narayanan, G. C. Stewart, M. M. Chengappa, L. Willard, W. Shuman, M. Wilkerson, and T. G. Nagaraja, Infect. Immun. 70, 4609 (2002).
13. L. Dini, P. Pagliara, and E. C. Carla, Microsc. Rea. Technol. 6, 530 (2002).
14. I. S. Mathiasen, I. N. Sergeev, L. Bastholm, F. Ellling, A. W. Norman, and M. Jaattela, J. Biol. Chem. 277, 30 738 (2002).
15. M. H. Nasr-Esfahani, R. Aboutorbi, E. Esfandiari, and M. Mardani. J. Assist. Reprod. Genet. 19, 477 (2002).
16. T. Bachleitner-Hofmann, M. Kees, and H. Gisslinger, Leuk Lymphoma. 43, 1535 (2002).
17. L. Zhong, F. Y. Chen, J. Y. Han, N. X. Shao, and R. R. Ou-Yang, Chin Med. J. (Engl). 116, 148 (2003).
18. Q. S. Shao, Z. Y. Ye, Z. Q. Ling, and J. J. Ke, World J. Gastroenterol. 11, 3451 (2005).
19. J. Zhu, H. Okumura, S. Ohtake, S. Nakamura, and S. Nakao, Oncol Rep. 10, 705 (2003).
20. K. H. Ryu, S. Y. Woo, M. Y. Lee, Y. J. Jung, E. S. Yoo, J. Y. Seoh, J. H. Kie, H. Y. Shin, and H. S. Ahn, Pediatr Hematol Oncol. 22, 609 (2005).
21. A. M. Evens, M. S. Tallman, and R. B. Gartenhaus, Leuk Res. 28, 891 (2004).
22. J. E. Li, W. L. Wu, Z. Y. Wang, and G. L. Sun, Acta Pharmacol. Sin. 23, 991 (2002).
23. M. P. Desai, V. Labhasetwar, E. Walter, R. J. Levy, and G. L. Amidon, Pharm. Res. 14, 1568 (1997).